KURIMOTO-EDUCATIONAL
20.4.2022 11:02:14 CEST | Business Wire | Press release
Kurimoto Educational Institute (KEI, Chairman: Dr. Hiroyuki Kurimoto), the parent organisation of the Nagoya University of Commerce (NUCB) received the official approval for the establishment of its boarding high school, NUCB International College (NIC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413006084/en/
World-Class Full Boarding High School in Japan
The plan to open the school in September 2022 is progressing as scheduled and NIC is now officially accepting applications from students around the world.
The co-educational institution is designed to provide a world-class education with excellent facilities and a rich natural environment, on its 200-acre campus, in Nisshin city, Japan.
School Outline
School Name: NUCB International College
Capacity: 225 students, Co-educational, Full boarding
Programme: Japanese Senior High School & International Baccalaureate Diploma Programme (IBDP)*
Year level range: 10-12. Student transfers accepted until Year 11.
Language of instruction: English
Location: 4-4 Sagamine, Komenoki, Nisshin, Aichi, Japan
Opening date: September 2022
*NUCB International College is a candidate school for the Diploma Programme. It is pursuing authorisation as an IB World School. Candidate status gives no guarantee that authorisation will be granted.
Educational excellence
NIC stands at the brink of an educational shift, being the only International Boarding High School in Japan implementing innovative early leadership education through the Harvard-style Case Method. Small classes enable personalised supervision by multinational faculty members with master's or doctoral degrees and faculty from affiliated business schools.
Boarding Education
With reference to international boarding school standards, boarding life is supported daily by House Supervisors and House Mentors. Through communal living in an international environment, participants learn the discipline and courtesy required of leaders in the context of diversity. NIC also offers a Summer School and the Bridging Programme (preparation for September enrolment). Plans are also underway for homestays, international exchange programmes, and cultural enrichment trips in Japan.
About Kurimoto Educational Institute
Parent organisation of NUCB Undergraduate School, NUCB Business School, and Nagoya International Junior and Senior High Schools, KEI promotes the high-quality internationalisation of education by acquiring international accreditations (AACSB, EQUIS, AMBA, and IBDP) for the schools it establishes, since 1935.
Click below to find out why NIC should be your number one choice for further studies.
https://ic.nucba.ac.jp/college/advantage/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413006084/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom